Supporting the findings of these in vitro assays, the overall survival among AML patients in IL- 2 treatment combined with histamine dihydrochloride (a drug administered to prevent relapse) was higher in the HLA-B-21M/X genotype group than in the HLA-B-21T/T genotype group (97). This evidence concerns the gene HLA-B and acute myeloid leukemia.